Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care in Turkey
Launched by SCARE (STUDY GROUP FOR CARBAPENEM RESISTANCE) · Mar 10, 2020
Trial Information
Current as of May 06, 2025
Unknown status
Keywords
ClinConnect Summary
Blood stream infection (BSI) is defined as the identification of a culprit pathogen in the blood culture sample of a participant. As such, and once contaminants are excluded, BSI is the only cause of sepsis where the presence of an infection and the pathogen are known with certainty. This makes BSI the perfect model of infection to study the effects of the micro-organism on the participant, and the effects of the antibiotics and other treatments on survival. There is an increasing trend in antimicrobial resistance rates among microorganisms that are associated with nosocomial infections tre...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 Years.
- • Hospital Acquired Bloodstream Infection (HA-BSI).
- • Treated in the ICU.
- • ICU acquired OR Hospital acquired prior to ICU admission
- Exclusion Criteria:
- • Patients that had a positive blood culture in the hospital and transferred to ICU for a different reason than specific treatment of the causes or consequences of HA-BSI.
- • Previous inclusion in the study.
- • HA-BSI is defined as a positive blood culture (BC) sampled after 48 hours following hospital admission.
About Scare (Study Group For Carbapenem Resistance)
Scare (Study Group for Carbapenem Resistance) is a dedicated clinical trial sponsor focused on addressing the critical global health challenge of carbapenem-resistant infections. By facilitating innovative research and fostering collaboration among healthcare professionals, researchers, and institutions, Scare aims to enhance understanding of carbapenem resistance mechanisms and promote the development of effective therapeutic strategies. Through rigorous clinical trials and data-driven insights, Scare is committed to advancing patient care and improving outcomes in the fight against antibiotic-resistant pathogens.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials